Amgen Beats Q3, Lifts Guidance as Three Trials Hit Endpoints
AMGN sits 62% above its 52-week low of $294.48.
Summary
Amgen delivered a clean Q3: revenue of $10.37 billion, up 8%, and adjusted EPS of $6.45, up 14% and ahead of forecasts, and management raised full-year revenue and adjusted EPS guidance. The quarter came with clinical wins — TEZSPIRE hit its Phase 3 endpoints in eosinophilic esophagitis, dazodalibep met its primary endpoint in Sjögren's disease, and an IMDELLTRA combination improved survival. That combination of a beat, a raise and pipeline validation is what traders pay for, and it lands with the stock near its 52-week high of $482.48. The 10-Q filed Nov. 3 already showed the $10,365 million revenue and $7.08 diluted EPS, with biosimilar erosion in Prolia and XGEVA offset by Repatha and newer products; today's release adds the adjusted numbers, the guidance raise and the trial readouts. Ten firms lifted price targets, ranging from $410 to $536, though ratings were left unchanged. The open question is obesity: RBC said it needs more MariTide data, not expected until 2027, before judging that program.
At the time of this announcement, AMGN was trading at $477.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $258.7B. The 52-week trading range was $294.48 to $482.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.